BlossomHill Posts $24.0M Q3 Loss; Pivotal SOLARA-2 Dosing Set for Q1 2027
BLSM sits 35% above its 52-week low of $11.02.
Summary
BlossomHill's Q3 8-K shows a $24.0 million net loss and $224.9 million in cash with runway into Q2 2028, alongside the already-released FDA dose alignment and pivotal SOLARA-2 plan for C797S-positive NSCLC.
Key Events · Earnings and Guidance · BLSM
-
Q3 Net Loss Widens to $24.0M
The net loss was $24.0 million, or ($1.29) per basic and diluted share, versus $16.0 million, or ($6.54) per share, in Q3 2025. R&D rose to $21.9 million from $14.7 million, driven by BH-30643 clinical work and BH-501284 IND-enabling costs.
-
Cash Runway Into Q2 2028
Cash and cash equivalents totaled $224.9 million at September 30, 2026, which the company says funds operations into the second quarter of 2028 — past the planned Q1 2027 SOLARA-2 first-patient dosing and BH-501284 IND filing.
-
Pivotal SOLARA-2 Dosing Set for Q1 2027
FDA aligned on 50 mg twice daily as the recommended Phase 2 dose for BH-30643. The single-arm pivotal Phase 2 SOLARA-2 trial in EGFR C797S-positive NSCLC is expected to dose its first patient in Q1 2027.
-
Foundation Medicine CDx Collaboration
BlossomHill is collaborating with Foundation Medicine to develop a companion diagnostic assay for the EGFR C797S resistance mutation, supporting biomarker-selected enrollment in the registrational program.
Analysis · BLSM · Life Sciences
The incremental news here is the financials, since the headline clinical items — FDA alignment on 50 mg twice daily and the registrational-intent SOLARA-2 trial — were already released this evening. The quarter brought a $24.0 million net loss ($1.29/share) on R&D of $21.9 million, up from $14.7 million a year ago as the BH-30643 program scales. With $224.9 million in cash, operations are funded into Q2 2028, covering both the Q1 2027 first-patient dosing in SOLARA-2 and the Q1 2027 BH-501284 IND without an immediate raise. The Foundation Medicine companion diagnostic collaboration also matters: a C797S assay is a practical prerequisite for enrolling a biomarker-selected pivotal trial.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BLSM was trading at $14.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $471.7M. The 52-week trading range was $11.02 to $27.99. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.